Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

An individual doesn’t develop heart disease in one day. It develops over several months and years. Therefore, it is crucial ...

Lexi Reed's journey has continued to inspire many people. Recently she took to her official Instagram handle and shared an ...

Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), with a price target of ...

A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for ...

Israeli troops crossed the border for the first time since 2006 in a ground operation targeting Hezbollah. The Israeli military called for evacuations in southern Lebanon. As a Crisis Builds ...

'Trust has become biggest casualty': What Army chief said on LAC standoff with China Army Chief Upendra Dwivedi stated that the situation along the LAC in eastern Ladakh is stable but sensitive ...